Citi analyst Yigal Nochomovitz lowered the firm’s price target on Cellectis to $24 from $36 and keeps a Buy rating on the shares. UCART22 looking initially promising on safety and efficacy, though the program is pivoting to an in-house manufactured version, Nochomovitz tells investors in a research note. The analyst dropped the price target to reflect higher pipeline risk. He says UCART123 CRS is a concern and single-dose DL2 efficacy is underwhelming.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLLS:
- Cellectis announces preliminary data for UCART22, UCART123
- Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
- Oppenheimer emerging biotech analysts to hold analyst/industry conference call
- Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
- Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
